Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Invest New Drugs. 2018 Jul 28;37(1):147–158. doi: 10.1007/s10637-018-0646-1

Table 1.

Demographics and baseline characteristics

Characteristic All Subjects (N = 36)
Gender, n (%)
 Male 9 (25.0%)
 Female 27 (75.0%)
Age (Years)
 Mean ± SD 58.3 ± 10.2
Race, n (%)
 Caucasian 31 (86.1%)
 Black or African American 3 (8.3%)
 Asian 2 (5.6%)
Weight (kg)
 Mean ± SD 80.9 ± 22.4
ECOG performance status, n (%)
 0 20 (55.6%)
 1 16 (44.4%)
Primary tumor type, n (%)
 Colorectal 15 (41.7%)
 Ovarian 14 (38.9%)
 Non-small cell lung 5 (13.9%)
 Small cell lung 1 (2.8%)
 Small bowel 1 (2.8%)
Prior radiotherapy, n (%)
 Yes 11 (30.6%)
 No 25 (69.4%)
Number of prior chemotherapy regimens
 2 4 (11.1%)
 ≥3 32 (88.9%)

SD standard deviation